{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:10:45Z","timestamp":1758892245454,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile isolates from patients with C. difficile infection (CDI) from two Phase 3 clinical trials of surotomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In both trials [Protocol MK-4261-005 (NCT01597505) conducted across Europe, North America and Israel; and Protocol MK-4261-006 (NCT01598311) conducted across North America, Asia-Pacific and South America], patients with CDI were randomized (1:1) to receive oral surotomycin (250\u2009mg twice daily) or oral vancomycin (125\u2009mg four times per day) for 10\u2009days. Stool samples were collected at baseline and C. difficile isolates were characterized by restriction endonuclease analysis (REA) and PCR ribotyping. Susceptibility testing was performed by agar dilution, according to CLSI recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 1147 patients were included in the microbiological modified ITT population. Of 992 recovered isolates, 922 (92.9%) were typed. There was a high association between REA groups and their corresponding predominant PCR ribotype (RT) for BI, DH, G and CF strains. REA group A showed more diverse PCR RTs. Overall, the most common strain was BI\/RT027 (20.3%) followed by Y\/RT014\/020 (15.0%) and DH\/RT106 (7.2%). The BI\/RT027 strain was particularly prevalent in Europe (29.9%) and Canada (23.6%), with lower prevalence in the USA (16.8%) and Australia\/New Zealand (3.4%). Resistance was most prevalent in the BI\/RT027 strain, particularly to metronidazole, vancomycin and moxifloxacin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A wide variation in C. difficile strains, both within and across different geographical regions, was documented by both REA and ribotyping, which showed overall good correlation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa297","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T19:52:41Z","timestamp":1596138761000},"page":"3120-3125","source":"Crossref","is-referenced-by-count":7,"title":["Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities"],"prefix":"10.1093","volume":"75","author":[{"given":"Adam","family":"Cheknis","sequence":"first","affiliation":[{"name":"Edward Hines, Jr. VA Hospital, Hines, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Devaris","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Chesnel","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne E","family":"Dale","sequence":"additional","affiliation":[{"name":"ACM Global Laboratories, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Nary","sequence":"additional","affiliation":[{"name":"ACM Global Laboratories, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan P","family":"Sambol","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. VA Hospital, Hines, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane M","family":"Citron","sequence":"additional","affiliation":[{"name":"R.M. Alden Research Laboratory, Culver City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard V","family":"Goering","sequence":"additional","affiliation":[{"name":"Creighton University, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Johnson","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. VA Hospital, Hines, IL, USA"},{"name":"Loyola University Medical Center, Maywood, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"2020101604550764300_dkaa297-B1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ng.2478","article-title":"Emergence and global spread of epidemic healthcare-associated Clostridium difficile","volume":"45","author":"He","year":"2013","journal-title":"Nat Genet"},{"key":"2020101604550764300_dkaa297-B2"},{"key":"2020101604550764300_dkaa297-B3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"key":"2020101604550764300_dkaa297-B4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","article-title":"Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)","volume":"14","author":"Davies","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2020101604550764300_dkaa297-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5009\/gnl.2014.8.1.1","article-title":"Clostridium difficile infection: a worldwide disease","volume":"8","author":"Burke","year":"2014","journal-title":"Gut Liver"},{"key":"2020101604550764300_dkaa297-B6","doi-asserted-by":"crossref","first-page":"510386","DOI":"10.1155\/2015\/510386","article-title":"The epidemiology and economic burden of Clostridium difficile infection in Korea","volume":"2015","author":"Choi","year":"2015","journal-title":"Biomed Res Int"},{"key":"2020101604550764300_dkaa297-B7","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1093\/cid\/cis319","article-title":"Current status of Clostridium difficile infection epidemiology","volume":"55","author":"Lessa","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020101604550764300_dkaa297-B8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1099\/jmm.0.036194-0","article-title":"Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage","volume":"61","author":"Valiente","year":"2012","journal-title":"J Med Microbiol"},{"author":"Johnson","key":"2020101604550764300_dkaa297-B9"},{"key":"2020101604550764300_dkaa297-B10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/cid\/ciu203","article-title":"Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain","volume":"58","author":"Lim","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020101604550764300_dkaa297-B11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020101604550764300_dkaa297-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anaerobe.2018.07.004","article-title":"Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains","volume":"54","author":"Kociolek","year":"2018","journal-title":"Anaerobe"},{"key":"2020101604550764300_dkaa297-B13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.anaerobe.2014.04.005","article-title":"International typing study of Clostridium difficile","volume":"28","author":"Manzo","year":"2014","journal-title":"Anaerobe"},{"key":"2020101604550764300_dkaa297-B14","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/JCM.02446-10","article-title":"Comparison of strain typing results for Clostridium difficile isolates from North America","volume":"49","author":"Tenover","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020101604550764300_dkaa297-B15","doi-asserted-by":"crossref","first-page":"ofw275","DOI":"10.1093\/ofid\/ofw275","article-title":"Primary outcomes from a Phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection","volume":"4","author":"Boix","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020101604550764300_dkaa297-B16","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1093\/jac\/dkx299","article-title":"Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial","volume":"72","author":"Daley","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020101604550764300_dkaa297-B17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.anaerobe.2018.05.009","article-title":"Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006\u20132009 to 2012\u20132015","volume":"53","author":"Cheknis","year":"2018","journal-title":"Anaerobe"},{"key":"2020101604550764300_dkaa297-B18","doi-asserted-by":"crossref","first-page":"e0118150","DOI":"10.1371\/journal.pone.0118150","article-title":"Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile","volume":"10","author":"Fawley","year":"2015","journal-title":"PLoS One"},{"year":"2012","key":"2020101604550764300_dkaa297-B19"},{"key":"2020101604550764300_dkaa297-B20"},{"key":"2020101604550764300_dkaa297-B21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/CMR.00082-09","article-title":"The changing epidemiology of Clostridium difficile infections","volume":"23","author":"Freeman","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2020101604550764300_dkaa297-B22","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2009.02.073","article-title":"Clostridium difficile infection caused by the epidemic BI\/NAP1\/027 strain","volume":"136","author":"O'Connor","year":"2009","journal-title":"Gastroenterology"},{"key":"2020101604550764300_dkaa297-B23"},{"key":"2020101604550764300_dkaa297-B24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.anaerobe.2009.09.005","article-title":"Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection","volume":"15","author":"Citron","year":"2009","journal-title":"Anaerobe"},{"key":"2020101604550764300_dkaa297-B25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cmi.2017.10.008","article-title":"The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011\u20132014","volume":"24","author":"Freeman","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2020101604550764300_dkaa297-B26","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/592257","article-title":"Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078","volume":"47","author":"Goorhuis","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3120\/33893235\/dkaa297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3120\/33893235\/dkaa297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T08:55:51Z","timestamp":1602838551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/11\/3120\/5880201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,8,3]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa297","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,8,3]]}}}